Last progress May 15, 2025 (6 months ago)
Introduced on May 15, 2025 by Joshua David Hawley
Read twice and referred to the Committee on Finance.
This bill would stop drug makers from writing off the cost of ads that target the general public. In short, companies could no longer claim a tax deduction for direct-to-consumer ads for prescription or compounded drugs. Ads aimed at regular people on TV, radio, billboards, and online (including social media and apps) would count. Ads in medical journals and similar periodicals would not count as direct-to-consumer ads and would still be deductible. The rule applies to companies that sponsor prescription drugs or own drug compounding facilities .
| Key point | What it means |
|---|---|
| Who is affected | Drug sponsors and owners of drug outsourcing facilities |
| What changes | No tax deduction for costs of direct-to-consumer ads for prescription or compounded drugs |
| What counts as DTC ads | Public-facing ads on TV, radio, billboards, and online/digital platforms (including social media and apps) |
| What does not count | Ads printed in journals and other periodicals |
| When | The provided text does not state an effective date |